<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Vries, R. de</title>
    <link>http://repub.eur.nl/res/aut/12902/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Nitrite- and nitroxyl-induced relaxation in porcine coronary (micro-) arteries: Underlying mechanisms and role as endothelium-derived hyperpolarizing factor(s) (Article)</title>
      <link>http://repub.eur.nl/res/pub/37461/</link>
      <pubDate>2012-11-01T00:00:00Z</pubDate>
      <description>To investigate the vasorelaxant efficacy of nitrite and nitroxyl (HNO) in porcine coronary (micro)arteries (PC(M)As), evaluating their role as endothelium-derived hyperpolarizing factors (EDHFs), preconstricted PCAs and PCMAs were exposed to UV light (a well-known inductor of nitrite; wave-length: 350-370 nm), nitrite, the HNO donor Angeli's salt, or bradykinin. UV light-induced relaxation of PCAs increased identically after endothelium removal and endothelial nitric oxide (NO) synthase (eNOS) blockade. UV light-induced relaxation diminished during Na+-K+-ATPase inhibition and S-nitrosothiol-depletion, and disappeared during NO scavenging with hydroxocobalamin or soluble guanylyl cyclase (sGC) inhibition with ODQ. Nitrite-induced relaxation of PCAs required millimolar levels, i.e., &gt;1000 times endogenous vascular nitrite. Angeli's salt relaxed PCMAs more potently than PCAs, and this was due to the fact that HNO directly activated sGC in PCMAs, whereas in PCAs this occurred following its conversion to NO only. sGC activation by NO/HNO resulted in Na+-K+-ATPase stimulation and Kvchannel activation. The HNO scavenger l-cysteine blocked bradykinin-induced relaxation in PCAs, and potentiated it in PCMAs. The latter did not occur in the presence of hydroxocobalamin, suggesting that it depended on l-cysteine-induced generation of vasorelaxant S-nitrosothiols. In all experimental setups, incubation with red wine extract mimicked the effects of ODQ. In conclusion, nitrite, via its conversion to NO and S-nitrosothiols, and HNO, either directly, or via its conversion to NO, mediate relaxant effects involving the sGC-cGMP pathway, Na+-K+-ATPase and/or Kvchannels. Red wine extract counteracts these beneficial effects. NO blocks nitrite activation, and HNO, but not nitrite, may act as EDHF in the coronary vascular bed. </description>
    </item> <item>
      <title>Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes (Article)</title>
      <link>http://repub.eur.nl/res/pub/34741/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description>Detailed evaluation of coronary function early in diabetes mellitus (DM)-associated coronary artery disease (CAD) development is difficult in patients. Therefore, we investigated coronary conduit and small artery function in a preatherosclerotic DM porcine model with type 2 characteristics. Streptozotocin-induced DM pigs on a saturated fat/cholesterol (SFC) diet (SFC + DM) were compared with control pigs on SFC and standard (control) diets. SFC + DM pigs showed DM-associated metabolic alterations and early atherosclerosis development in the aorta. Endothelium-dependent vasodilation to bradykinin (BK), with or without blockade of nitric oxide (NO) synthase, endothelium-independent vasodilation to an exogenous NO-donor (S-nitroso-N-acetylpenicillamine), and vasoconstriction to endothelin (ET)-1 with blockade of receptor subtypes, were assessed in vitro. Small coronary arteries, but not conduit vessels, showed functional alterations including impaired BK-induced vasodilatation due to loss of NO (P &lt; 0.01 vs. SFC and control) and reduced vasoconstriction to ET-1 (P &lt; 0.01 vs. SFC and control), due to a decreased ETa receptor dominance. Other vasomotor responses were unaltered. In conclusion, this model demonstrates specific coronary microvascular alterations with regard to NO and ET-1 systems in the process of early atherosclerosis in DM. In particular, the altered ET-1 system correlated with hyperglycemia in atherogenic conditions, emphasizing the importance of this system in DM-associated CAD development. </description>
    </item> <item>
      <title>Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: Possible contribution to an atherogenic lipoprotein profile (Article)</title>
      <link>http://repub.eur.nl/res/pub/26489/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>Context: Plasma lipoprotein-associated phospholipase A2(Lp-PLA2) predicts incident cardiovascular disease and is associated preferentially with negatively charged apolipoprotein B-containing lipoproteins. The plasma cholesteryl ester transfer (CET) process, which contributes to low highdensity lipoprotein cholesterol and small, dense low-density lipoproteins, is affected by the composition and concentration of apolipoprotein B-containing cholesteryl ester acceptor lipoproteins. Objective: We tested relationships of CET with Lp-PLA2in subjects with and without metabolicsyndrome (MetS). Design and Setting: In 68 subjects with MetS and 74 subjects without MetS, plasma Lp-PLA2mass, cholesterol esterification (EST), lecithin:cholesterol acyltransferase (LCAT) activity level, CET, CET protein (CETP) mass, and lipoproteins were measured. Results: EST, LCAT activity, CET (P&lt;0.001 for all), and CETP (P&lt;0.030) were increased, and Lp-PLA2was decreased (P&lt;0.043) in MetS. CET was correlated positively with Lp-PLA2in subjects with and without MetS (P = 0.05 for both). EST and LCAT activity were unrelated to Lp-PLA2, despite a positive correlation between EST and CET (P = 0.001). After controlling for age, sex, and diabetes status, CET was determined by Lp-PLA2in the whole group (β = 0.245; P = 0.001), and in subjects with (β = 0.304; P = 0.001) and without MetS (β = 0.244; P = 0.006) separately, independently of triglycerides and CETP. Conclusions: PlasmaCETis related to Lp-PLA2in subjects withandwithout MetS.Theprocess of CET, but not EST, may be influenced by Lp-PLA2. These findings provide a rationale to evaluate whether maneuvers that inhibit Lp-PLA2will reduce CET, and vice versa to document effects of CETP inhibition on Lp-PLA2. Copyright </description>
    </item> <item>
      <title>Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries (Article)</title>
      <link>http://repub.eur.nl/res/pub/27369/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>The sensory neuropeptide calcitonin gene-related peptide (CGRP) plays a role in primary headaches, and CGRP receptor antagonists are effective in migraine treatment. CGRP is a potent vasodilator, raising the possibility that antagonism of its receptor could have cardiovascular effects. We therefore investigated the effects of the antimigraine CGRP receptor antagonist telcagepant (MK-0974) [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl) azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1- yl)piperidine-1-carboxamide] on human isolated coronary arteries. Arteries with different internal diameters were studied to assess the potential for differential effects across the coronary vascular bed. The concentration- dependent relaxation responses to human αCGRP were greater in distal coronary arteries (i.d. 600-1000 μm; Emax= 83 ± 7%) than proximal coronary arteries (i.d. 2-3 mm; Emax= 23 ± 9%), coronary arteries from explanted hearts (i.d. 3-5 mm; Emax= 11 ± 3%), and coronary arterioles (i.d. 200-300 μm; Emax= 15 ± 7%). Telcagepant alone did not induce contraction or relaxation of these coronary blood vessels. Pretreatment with telcagepant (10 nM to 1 μM) antagonized αCGRP-induced relaxation competitively in distal coronary arteries (pA2= 8.43 ± 0.24) and proximal coronary arteries and coronary arterioles (1 μM telcagepant, giving pKB= 7.89 ± 0.13 and 7.78 ± 0.16, respectively). αCGRP significantly increased cAMP levels in distal, but not proximal, coronary arteries, and this was abolished by pretreatment with telcagepant. Immunohistochemistry revealed the expression and colocalization of the CGRP receptor elements calcitonin-like receptor and receptor activity-modifying protein 1 in the smooth muscle cells in the media layer of human coronary arteries. These findings in vitro support the cardiovascular safety of CGRP receptor antagonists and suggest that telcagepant is unlikely to induce coronary side effects under normal cardiovascular conditions. Copyright </description>
    </item> <item>
      <title>Mast cell degranulation mediates bronchoconstriction via serotonin and not via renin release (Article)</title>
      <link>http://repub.eur.nl/res/pub/20212/</link>
      <pubDate>2010-08-01T00:00:00Z</pubDate>
      <description>To verify the recently proposed concept that mast cell-derived renin facilitates angiotensin II-induced bronchoconstriction bronchial rings from male Sprague-Dawley rats were mounted in Mulvany myographs, and exposed to the mast cell degranulator compound 48/80 (300μg/ml), angiotensin I, angiotensin II, bradykinin or serotonin (5-hydroxytryptamine, 5-HT), in the absence or presence of the renin inhibitor aliskiren (10μmol/l), the ACE inhibitor captopril (10μmol/l), the angiotensin II type 1 (AT1) receptor blocker irbesartan (1μmol/l), the mast cell stabilizer cromolyn (0.3mmol/l), the 5-HT2A/2C receptor antagonist ketanserin (0.1μmol/l) or the α1-adrenoceptor antagonist phentolamine (1μmol/l). Bath fluid was collected to verify angiotensin generation. Bronchial tissue was homogenized to determine renin, angiotensinogen and serotonin content. Compound 48/80 contracted bronchi to 24±4% of the KCl-induced contraction. Ketanserin fully abolished this effect, while cromolyn reduced the contraction to 16±5%. Aliskiren, captopril, irbesartan and phentolamine did not affect this response, and the angiotensin I and II levels in the bath fluid after 48/80 exposure were below the detection limit. Angiotensin I and II equipotently contracted bronchi. Captopril shifted the angiotensin I curve ≈10-fold to the right, whereas irbesartan fully blocked the effect of angiotensin II. Bradykinin-induced constriction was shifted ≈100-fold to the left with captopril. Serotonin contracted bronchi, and ketanserin fully blocked this effect. Finally, bronchial tissue contained serotonin at micromolar levels, whereas renin and angiotensinogen were undetectable in this preparation. In conclusion, mast cell degranulation results in serotonin-induced bronchoconstriction, and is unlikely to involve renin-induced angiotensin generation.</description>
    </item> <item>
      <title>Steroidogenesis vs. steroid uptake in the heart: Do corticosteroids mediate effects via cardiac mineralocorticoid receptors? (Article)</title>
      <link>http://repub.eur.nl/res/pub/27885/</link>
      <pubDate>2010-05-01T00:00:00Z</pubDate>
      <description>Objective: To test whether glucocorticoids act as the endogenous agonist of cardiac mineralocorticoid receptors, we evaluated the cardiac effects of aldosterone and corticosterone and cardiac steroidogenesis vs. steroid uptake from plasma. Methods and Results: Both corticosterone and aldosterone increased left ventricular pressure in the rat heart. Aldosterone decreased coronary flow, whereas corticosterone increased it. All corticosterone effects were blocked by the glucocorticoid receptor antagonist, RU486, and unaltered by the mineralocorticoid receptor antagonist, canrenoate, or the 11β- hydroxysteroid dehydrogenase (HSD11B)2 inhibitor, carbenoxolone. Unlike mineralocorticoid receptor blockade, RU486 did not ameliorate postischemia infarct size and arrhythmias. Corticosterone, when added to the perfusion buffer, rapidly accumulated at cardiac tissue sites, reaching steady-state levels that were identical to those in coronary effluent, independently of the presence of aldosterone, RU486 or canrenoate. After stopping the perfusion, cardiac corticosterone fully washed away with a half-life of less than 1 min. Measurements of steroid-synthesizing enzyme gene expression levels in human ventricular and atrial tissue pieces from heart-beating organ donors, patients with end-stage heart failure and hypertrophic cardiomyopathy patients revealed that under no condition, the human heart was capable of synthesizing aldosterone or cortisol de novo. Yet, expression of HSD11B1, HSD11B2, mineralocorticoid receptors and glucocorticoid receptors was found, and HSD11B2 and mineralocorticoid receptors were upregulated in pathological conditions. Moreover, aldosterone reduced cardiac inotropy in a Na+/K+/2Cl-cotransporter-dependent manner. Conclusion: Both cortisol/corticosterone and aldosterone accumulate in the cardiac interstitium. The presence of HSD11B2 and mineralocorticoid receptors/glucocorticoid receptors at cardiac tissue sites allows both steroids to exert their effects via separate mechanisms. </description>
    </item> <item>
      <title>Light-induced vs. bradykinin-induced relaxation of coronary arteries: Do S-nitrosothiols act as endothelium-derived hyperpolarizing factors? (Article)</title>
      <link>http://repub.eur.nl/res/pub/24722/</link>
      <pubDate>2009-08-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Light-induced relaxation depends on S-nitrosothiols. S-Nitrosothiols may also serve as endothelium-derived hyperpolarizing factors, mediating the relaxant response of porcine coronary arteries (PCAs) to bradykinin. Here we compared the mechanism of light-induced and bradykinin-induced PCA relaxation. METHODS: PCAs were mounted in organ baths in the dark, preconstricted and exposed to polychromatic light (5 min) or 100 nmol/l bradykinin. RESULTS: Light relaxed PCAs by maximally 71 ± 1%. S-Nitrosothiol depletion abolished this relaxation. Relaxations diminished following repetitive light exposures, particularly if the dark periods between the light exposures were less than 10 min, and increased following endothelium removal or nitric oxide synthase blockade with N-nitro-L-arginine methyl ester (L-NAME), despite the prevention of guanosine-3′,5′-cyclic monophosphate generation by the latter two procedures. Thus, reloading of the storage pools occurs in the dark, endothelial nitric oxide inhibits this process and photorelaxation does not depend on guanosine-3′,5′-cyclic monophosphate. Bradykinin relaxed PCAs by 69 ± 3%. The nitric oxide scavenger hydroxocobalamin and the Na-K ATPase inhibitor ouabain abolished the responses to bradykinin and light. The guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one abolished the response to light, and, like L-NAME, blocked the response to bradykinin by more than 50%. On top of L-NAME, intermediate and small conductance Ca-dependent K channel (IKCa/SKCa) blockade further reduced the response to bradykinin and enhanced photorelaxation. CONCLUSION: Photorelaxation depends on stored S-nitrosothiols and their release/synthesis is negatively affected by endothelial nitric oxide and IKCa/SKCa. S-Nitrosothiols activate endothelial IKCa/SKCa and, via guanylyl cyclase, smooth muscle Na-K ATPase. Thus, they possess all properties of a bradykinin-induced endothelium-derived hyperpolarizing factor. </description>
    </item> <item>
      <title>Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus (Article)</title>
      <link>http://repub.eur.nl/res/pub/18394/</link>
      <pubDate>2009-03-01T00:00:00Z</pubDate>
      <description>Background: The high-density lipoprotein (HDL)-associated anti-oxidative and anti-inflammatory enzyme, paraoxonase-I, has been found previously to be lower in type 2 diabetes mellitus. We studied whether statin and fibrate treatment, alone and in combination, affect serum paraoxonase-I activity in conjunction with changes in HDL cholesterol in diabetic patients. Subjects and methods: A placebo-controlled crossover study was carried out in 14 type 2 diabetic patients to test the effect of 8 weeks of active treatment with simvastatin (40 mg daily), bezafibrate (400 mg daily), and their combination on serum paraoxonase-I activity, measured as its activity towards arylesterase and paraoxon. Serum paraoxonase-I activity was also compared between these diabetic patients and 49 non-diabetic control subjects. Results: Serum arylesterase activity was lower in type 2 diabetic patients compared to control subjects (P &lt; 0·001), but the difference in paraoxonase activity was not significant (P = 0·22). Neither arylesterase (P = 0·24) nor paraoxonase activity (P = 0·37) was increased in response to treatment, despite higher HDL cholesterol and apolipoprotein A-I during combination therapy (P &lt; 0·05 for both). Conclusion: Short-term administration of simvastatin and bezafibrate, even when combined, is ineffective in raising serum paraoxonase-I activity in type 2 diabetes.</description>
    </item> <item>
      <title>Reduced frequency of blood group Lewis a-b- in female Type 1 diabetes patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/29795/</link>
      <pubDate>2008-02-01T00:00:00Z</pubDate>
      <description>Aims: To examine a disputed association between the Lewis(a-b-) phenotype and Type 1 diabetes (T1D). Methods: Lewis red blood cell phenotyping was performed for 97 T1D White patients and 100 control subjects using monoclonal antibodies. Two historical cohorts were also included as a control population. Results: T1D patients had a lower frequency (4.1%) of Lewis(a-b-) blood group compared with simultaneously tested healthy control subjects (10.0%) and the historical control group (11.1%, P = 0.02). Male T1D patients showed a Lewis(a-b-) frequency of 8.0%, which was similar to both matched healthy male donors (9.8%) and historical (9.5%) male control subjects. Unexpectedly, none of the female T1D patients displayed Lewis(a-b-) phenotype, vs. 10.3% and 10.8% of female control subjects (P = 0.039 and 0.017). Conclusions: The Lewis(a-b-) phenotype occurs less frequently in T1D compared with healthy control subjects with a strong female gender bias. </description>
    </item> <item>
      <title>Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor (Article)</title>
      <link>http://repub.eur.nl/res/pub/35879/</link>
      <pubDate>2007-12-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: Mannose 6-phosphate receptors (M6PR) bind both renin and prorenin, and such binding contributes to renin/prorenin clearance but not to angiotensin generation. Here, we evaluated the kinetics of renin/prorenin binding to the recently discovered human (pro)renin receptor (h(P)RR), and the idea that such binding underlies tissue angiotensin generation. METHODS AND RESULTS: Vascular smooth muscle cells from control rats and transgenic rats with smooth muscle h(P)RR overexpression were incubated at 4 or 37°C with human renin or prorenin. Incubation at 37°C greatly increased binding, suggesting that (pro)renin-binding receptors cycle between the intracellular compartment and the cell surface. Blockade of the M6PR reduced binding by approximately 50%. During M6PR blockade, h(P)RR cells bound twice as much prorenin as control cells, while renin binding was unaltered. Incubation of h(P)RR (but not control) cells with prorenin + angiotensinogen yielded more angiotensin than expected on the basis of the activity of soluble prorenin, whereas angiotensin generation during incubation of both cell types with renin + angiotensinogen was entirely due to soluble renin. The renin + angiotensinogen-induced vasoconstriction of isolated iliac arteries from control and transgenic rats was also due to soluble renin only. The recently proposed (P)RR antagonist 'handle region peptide', which resembles part of the prosegment, blocked neither prorenin binding nor angiotensin generation. CONCLUSIONS: H(P)RRs preferentially bind prorenin, and such binding results in angiotensin generation, most likely because binding results in prorenin activation. </description>
    </item> <item>
      <title>Effects of female sex hormones on responses to CGRP, acetylcholine, and 5-HT in rat isolated arteries (Article)</title>
      <link>http://repub.eur.nl/res/pub/35487/</link>
      <pubDate>2007-04-01T00:00:00Z</pubDate>
      <description>Background. - Female sex hormones are implicated in the modulation of reactivity of a wide range of blood vessels under physiological as well as pathological conditions. Migraine, a neurovascular syndrome, is 3 times more prevalent in women during their reproductive period than in men. Objective. - This study sets out to investigate the effects of the female sex steroids, 17β-estradiol and progesterone (separately and in combination) on vasoactive responses to calcitonin gene-related peptide (CGRP), acetylcholine, and 5-hydroxytryptamine (5-HT) in rat isolated mesenteric, caudal, and basilar arteries. Methods. - Female Sprague-Dawley rats were ovariectomized (Day 0) and 7 days later subcutaneously implanted with pellets releasing over a 21-day period 17β-estradiol (0.25 mg), progesterone (50 mg), their combination, or placebo. On days 25-28, the animals were killed, arteries isolated and mounted in Mulvany myographs, and cumulative concentration response curves to CGRP, acetylcholine, and 5-HT were constructed. Results. - The relaxant responses to CGRP were significantly potentiated in mesenteric and caudal arteries from rats treated with 17β-estradiol as compared to the placebo-treated rats. Acetylcholine-induced relaxations were potentiated in the caudal artery from rats treated with the combination of 17β-estradiol and progesterone, as compared to that from placebo-treated rats. The 5-HT-induced contractions in the 3 arteries were not significantly different in efficacy or potency. Conclusion. - Our results show that 17β-estradiol potentiates CGRP-induced relaxations in the mesenteric and caudal arteries, while the combination treatment enhances acetylcholine-induced relaxations in the caudal artery. Although these in vitro experiments have been carried out in rats and a direct extrapolation to migraine in humans is not possible, our results may provide a new avenue to study the effects of sex steroids on vascular reactivity. </description>
    </item> <item>
      <title>Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries (Article)</title>
      <link>http://repub.eur.nl/res/pub/31787/</link>
      <pubDate>2007-03-01T00:00:00Z</pubDate>
      <description>Capsaicin, a pungent constituent from red chilli peppers, activates sensory nerve fibres via transient receptor potential vanilloid receptors type 1 (TRPV1) to release neuropeptides like calcitonin gene-related peptide (CGRP) and substance P. Capsaicin-sensitive nerves are widely distributed in human and porcine vasculature. In this study, we examined the mechanism of capsaicin-induced relaxations, with special emphasis on the role of CGRP, using various pharmacological tools. Segments of human and porcine proximal and distal coronary arteries, as well as cranial arteries, were mounted in organ baths. Concentration response curves to capsaicin were constructed in the absence or presence of the CGRP receptor antagonist olcegepant (BIBN4096BS, 1 μM), the neurokinin NK1receptor antagonist L-733060 (0.5 μM), the voltage-sensitive calcium channel blocker ruthenium red (100 μM), the TRPV1 receptor antagonist capsazepine (5 μM), the nitric oxide synthetase inhibitor Nω-nitro-l-arginine methyl ester HCl (l-NAME; 100 μM), the gap junction blocker 18α-glycyrrhetinic acid (10 μM), as well as the RhoA kinase inhibitor Y-27632 (1 μM). Further, we also used the K+channel inhibitors 4-aminopyridine (1 mM), charybdotoxin (0.5 μM)+apamin (0.1 μM) and iberiotoxin (0.5 μM)+apamin (0.1 μM). The role of the endothelium was assessed by endothelial denudation in distal coronary artery segments. In distal coronary artery segments, we also measured levels of cyclic adenosine monophosphate (cAMP) after exposure to capsaicin, and in human segments, we also assessed the amount of CGRP released in the organ bath fluid after exposure to capsaicin. Capsaicin evoked concentration-dependent relaxant responses in precontracted arteries, but none of the above-mentioned inhibitors did affect these relaxations. There was no increase in the cAMP levels after exposure to capsaicin, unlike after (exogenously administered) α-CGRP. Interestingly, there were significant increases in CGRP levels after exposure to vehicle (ethanol) as well as capsaicin, although this did not induce relaxant responses. In conclusion, the capsaicin-induced relaxations of the human and porcine distal coronary arteries are not mediated by CGRP, NK1, NO, vanilloid receptors, voltage-sensitive calcium channels, K+channels or cAMP-mediated mechanisms. Therefore, these relaxant responses to capsaicin are likely to be attributed to a non-specific, CGRP-independent mechanism. </description>
    </item> <item>
      <title>Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin (Article)</title>
      <link>http://repub.eur.nl/res/pub/35617/</link>
      <pubDate>2007-02-01T00:00:00Z</pubDate>
      <description>Background. - The prevalence of migraine is 2 to 3-fold higher in females than in males, and it is intricately related to the levels of female sex hormones. These hormones may regulate the synthesis and receptor expression of calcitonin gene-related peptide (CGRP), which mediates neurogenic dural vasodilatation and is implicated in migraine pathogenesis. Objective. - To investigate the effects of the female sex steroids, 17β-estradiol and progesterone, separately and in combination, on dural vasodilatation induced by αCGRP, periarterial electrical stimulation and capsaicin in ovariectomized rats, using intravital microscopy. Methods. - Sprague-Dawley rats were ovariectomized and, 7 days later, subcutaneously implanted with 21-day release pellets of 17β-estradiol, progesterone, their combination or placebo. On day 19 to 21, the animals were anesthetized, overlying bone thinned to visualize the middle meningeal artery and vasodilator responses to αCGRP (10 to 3000 ng kg-1), periarterial electrical stimulation (25 to 125 μA) and capsaicin (0.3 to 18 μg kg-1) elicited. Results. - There were no significant differences in the vasodilator potency or efficacy of αCGRP or capsaicin in the different groups studied. In contrast, the vasodilator response to electrical stimulation was significantly higher in rats treated with 17β-estradiol (Emax:157 ± 19%) as compared to those observed after placebo treatment (Emax:93 ± 11%). Conclusion. - Our results show that, in contrast to CGRP- or capsaicin-induced dural vasodilatation, 17β-estradiol enhanced neurogenic vasodilatation, suggesting increased CGRP release from perivascular nerves. This may be one of the mechanisms through which 17β-estradiol exacerbates migraine in women. </description>
    </item> <item>
      <title>Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13594/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>Somatic angiotensin-converting enzyme (ACE) contains 2 domains (C-domain
      and N-domain) capable of hydrolyzing angiotensin I (Ang I) and bradykinin.
      Here we investigated the effect of the selective C-domain and N-domain
      inhibitors RXPA380 and RXP407 on Ang I-induced vasoconstriction of porcine
      femoral arteries (PFAs) and bradykinin-induced vasodilation of
      preconstricted porcine coronary microarteries (PCMAs). Ang I
      concentration-dependently constricted PFAs. RXPA380, at concentrations &gt;1
      mumol/L, shifted the Ang I concentration-response curve (CRC) 10-fold to
      the right. This was comparable to the maximal shift observed with the ACE
      inhibitors (ACEi) quinaprilat and captopril. RXP407 did not affect Ang I
      at concentrations &lt; or =0.1 mmol/L. Bradykinin concentration-dependently
      relaxed PCMAs. RXPA380 (10 micromol/L) and RXP407 (0.1 mmol/L) potentiated
      bradykinin, both inducing a leftward shift of the bradykinin CRC that
      equaled approximately 50% of the maximal shift observed with quinaprilat.
      Ang I added to blood plasma disappeared with a half life (t(1/2)) of
      42+/-3 minutes. Quinaprilat increased the t(1/2) approximately 4-fold,
      indicating that 71+/-6% of Ang I metabolism was attributable to ACE.
      RXPA380 (10 micromol/L) and RXP407 (0.1 mmol/L) increased the t(1/2)
      approximately 2-fold, thereby suggesting that both domains contribute to
      conversion in plasma. In conclusion, tissue Ang I-II conversion depends
      exclusively on the ACE C-domain, whereas both domains contribute to
      conversion by soluble ACE and to bradykinin degradation at tissue sites.
      Because tissue ACE (and not plasma ACE) determines the hypertensive
      effects of Ang I, these data not only explain why N-domain inhibition does
      not affect Ang I-induced vasoconstriction in vivo but also why ACEi exert
      blood pressure-independent effects at low (C-domain-blocking) doses.</description>
    </item> <item>
      <title>Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF? (Article)</title>
      <link>http://repub.eur.nl/res/pub/13351/</link>
      <pubDate>2004-05-01T00:00:00Z</pubDate>
      <description>1. To investigate whether S-nitrosothiols, in addition to NO, mediate
      bradykinin-induced vasorelaxation, porcine coronary microarteries (PCMAs)
      were mounted in myographs. 2. Following preconstriction,
      concentration-response curves (CRCs) were constructed to bradykinin, the
      NO donors S-nitroso-N-penicillamine (SNAP) and diethylamine NONOate
      (DEA-NONOate) and the S-nitrosothiols L-S-nitrosocysteine (L-SNC) and
      D-SNC. All agonists relaxed PCMAs. L-SNC was approximately 5-fold more
      potent than D-SNC. 3. The guanylyl cyclase inhibitor ODQ and the NO
      scavenger hydroxocobalamin induced a larger shift of the bradykinin CRC
      than the NO synthase inhibitor L-NAME, although all three inhibitors
      equally suppressed bradykinin-induced cGMP responses. 4. Complete blockade
      of bradykinin-induced relaxation was obtained with L-NAME in the presence
      of the large- and intermediate-conductance Ca(2+)-activated K(+)-channel
      (BK(Ca), IK(Ca)) blocker charybdotoxin and the small-conductance
      Ca(2+)-activated K(+)-channel (SK(Ca)) channel blocker apamin, but not in
      the presence of L-NAME, apamin and the BK(Ca) channel blocker iberiotoxin.
      5. Inhibitors of cytochrome P450 epoxygenase, cyclooxygenase,
      voltage-dependent K(+) channels and ATP-sensitive K(+) channels did not
      affect bradykinin-induced relaxation. 6. SNAP-, DEA-NONOate- and
      D-SNC-induced relaxations were mediated entirely by the NO-guanylyl
      cyclase pathway. L-SNC-induced relaxations were partially blocked by
      charybdotoxin+apamin, but not by iberiotoxin+apamin, and this blockade was
      abolished following endothelium removal. ODQ, but not hydroxocobalamin,
      prevented L-SNC-induced increases in cGMP, and both drugs shifted the
      L-SNC CRC 5-10-fold to the right. 7. L-SNC hyperpolarized intact and
      endothelium-denuded coronary arteries. 8. Our results support the concept
      that bradykinin-induced relaxation is mediated via de novo synthesized NO
      and a non-NO, endothelium-derived hyperpolarizing factor (EDHF).
      S-nitrosothiols, via stereoselective activation of endothelial IK(Ca) and
      SK(Ca) channels, and through direct effects on smooth muscle cells, may
      function as an EDHF in porcine coronary microarteries.</description>
    </item> <item>
      <title>Vasoconstriction is determined by interstitial rather than circulating angiotensin II. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13005/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>1. We investigated why angiotensin (Ang) I and II induce vasoconstriction
      with similar potencies, although Ang I-II conversion is limited. 2.
      Construction of concentration-response curves to Ang I and II in porcine
      femoral arteries, in the absence or presence of the AT(1) or AT(2)
      receptor antagonists irbesartan and PD123319, revealed that the
      approximately 2 fold difference in potency between Ang I and II was not
      due to stimulation of different AT receptor populations by exogenous and
      locally generated Ang II. 3. Measurement of Ang I and II and their
      metabolites at the time of vasoconstriction confirmed that, at equimolar
      application of Ang I and II, bath fluid Ang II during Ang I was
      approximately 18 times lower than during Ang II and that Ang II was by far
      the most important metabolite of Ang I. Tissue Ang II was 2.9+/-1.5% and
      12.2+/-2.4% of the corresponding Ang I and II bath fluid levels, and was
      not affected by irbesartan or PD123319, suggesting that it was located
      extracellularly. 4. Since approximately 15% of tissue weight consists of
      interstitial fluid, it can be calculated that interstitial Ang II levels
      during Ang II resemble bath fluid Ang II levels, whereas during Ang I they
      are 8.8 - 27 fold higher. Consequently at equimolar application of Ang I
      and II, the interstitial Ang II levels differ only 2 - 4 fold. 5.
      Interstitial, rather than circulating Ang II determines vasoconstriction.
      Arterial Ang I, resulting in high interstitial Ang II levels via its local
      conversion by ACE, may be of greater physiological importance than
      arterial Ang II.</description>
    </item> <item>
      <title>Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade (Article)</title>
      <link>http://repub.eur.nl/res/pub/9693/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>ACE inhibitors block B(2) receptor desensitization, thereby potentiating
          bradykinin beyond blocking its hydrolysis. Angiotensin (Ang)-(1-7) also
          acts as an ACE inhibitor and, in addition, may stimulate bradykinin
          release via angiotensin II type 2 receptors. In this study we compared the
          bradykinin-potentiating effects of Ang-(1-7), quinaprilat, and captopril.
          Porcine coronary arteries, obtained from 32 pigs, were mounted in organ
          baths, preconstricted with prostaglandin F(2alpha), and exposed to
          quinaprilat, captopril, Ang-(1-7), and/or bradykinin. Bradykinin induced
          complete relaxation (pEC(50)=8.11+/-0.07, mean+/-SEM), whereas
          quinaprilat, captopril, and Ang-(1-7) alone were without effect.
          Quinaprilat shifted the bradykinin curve to the left in a biphasic manner:
          a 5-fold shift at concentrations that specifically block the C-domain (0.1
          to 1 nmol/L) and a 10-fold shift at concentrations that block both
          domains. Captopril and Ang-(1-7) monophasically shifted the bradykinin
          curve to the left, by a factor of 10 and 5, respectively. A 5-fold shift
          was also observed when Ang-(1-7) was combined with 0.1 nmol/L quinaprilat.
          Repeated exposure of porcine coronary arteries to 0.1 micromol/L
          bradykinin induced B(2) receptor desensitization. The addition of 10
          micromol/L quinaprilat or Ang-(1-7) to the bath, at a time when bradykinin
          alone was no longer able to induce relaxation, fully restored the relaxant
          effects of bradykinin. Angiotensin II type 1 or 2 receptor blockade did
          not affect any of the observed effects of Ang-(1-7). In conclusion,
          Ang-(1-7), like quinaprilat and captopril, potentiates bradykinin by
          acting as an ACE inhibitor. Bradykinin potentiation is maximal when both
          the ACE C- and N-terminal domains are inhibited. The inhibitory effects of
          Ang-(1-7) are limited to the ACE C-domain, raising the possibility that
          Ang-(1-7) synergistically increases the blood pressure-lowering effects of
          N-domain-specific ACE inhibitors.</description>
    </item> <item>
      <title>AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction (Article)</title>
      <link>http://repub.eur.nl/res/pub/9789/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>To investigate the functional consequences of postinfarct cardiac
      angiotensin (ANG) type 2 (AT(2)) receptor upregulation, rats underwent
      coronary artery ligation or sham operation and were infused with ANG II
      3-4 wk later, when scar formation is complete. ANG II increased mean
      arterial pressure (MAP) more modestly in infarcted animals than in sham
      animals. The AT(1) receptor antagonist irbesartan, but not the AT(2)
      receptor antagonist PD123319, decreased MAP and antagonized the ANG
      II-mediated systemic hemodynamic effects. Myocardial (MVC) but not renal
      vascular conductance (RVC) was diminished in infarcted versus sham rats.
      ANG II did not affect MVC and reduced RVC in all rats. MVC was unaffected
      by irbesartan and PD123319 in all animals. However, with PD123319, ANG II
      reduced MVC in sham but not infarcted animals, and, with irbesartan, ANG
      II increased MVC in infarcted but not sham animals. Irbesartan increased
      RVC and antagonized the ANG II-mediated renal effects in all animals. RVC,
      at baseline or with ANG II, was not affected by PD123319 in infarcted and
      sham animals. In conclusion, coronary but not renal AT(2) receptor
      stimulation results in vasodilation, and this effect is enhanced in
      infarcted rats.</description>
    </item> <item>
      <title>L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12885/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>1. NO synthase (NOS)inhibitors partially block bradykinin (BK)-mediated
          vasorelaxation. Here we investigated whether this is due to incomplete NOS
          inhibition and/or NO release from storage sites. We also studied the
          mechanism behind ACE inhibitor-mediated BK potentiation. 2. Porcine
          coronary arteries (PCAs) were mounted in organ baths, preconstricted, and
          exposed to BK or the ACE-resistant BK analogue Hyp(3)-Tyr(Me)(8)-BK
          (HT-BK) with or without the NOS inhibitor L-NAME (100 microM), the NO
          scavenger hydroxocobalamin (200 microM), the Ca(2+)-dependent K(+)-channel
          blockers charybdotoxin+apamin (both 100 nM), or the ACE inhibitor
          quinaprilat (10 microM). 3. BK and HT-BK dose-dependently relaxed
          preconstricted vessels (pEC(50) 8.0+/-0.1 and 8.5+/-0.2, respectively).
          pEC(50)'s were approximately 10 fold higher with quinaprilat, and
          approximately 10 fold lower with L-NAME or charybdotoxin+apamin. Complete
          blockade was obtained with hydroxocobalamin or L-NAME+
          charybdotoxin+apamin. 4. Repeated exposure to 100 nM BK or HT-BK, to
          deplete NO storage sites, produced progressively smaller vasorelaxant
          responses. With L-NAME, the decrease in response occurred much more
          rapidly. L-Arginine (10 mM) reversed the effect of L-NAME. 5. Adding
          quinaprilat to the bath following repeated exposure (with or without
          L-NAME), at the time BK and HT-BK no longer induced relaxation, fully
          restored vasorelaxation, while quinaprilat alone had no effect.
          Quinaprilat also relaxed vessels that, due to pretreatment with
          hydroxocobalamin or L-NAME+charybdotoxin+apamin, previously had not
          responded to BK. 6. In conclusion, L-NAME-resistant BK-induced relaxation
          in PCAs depends on NO from storage sites, and is mediated via stimulation
          of guanylyl cyclase and/or Ca(2+)-dependent K(+)-channels. ACE inhibitors
          potentiate BK independent of their effect on BK metabolism.</description>
    </item> <item>
      <title>New and potent inhibitors of nitric oxide synthase reduce motor activity in mice (Article)</title>
      <link>http://repub.eur.nl/res/pub/31867/</link>
      <pubDate>1997-09-01T00:00:00Z</pubDate>
      <description>Potent inhibitors of nitric oxide synthase (NOS), 3-bromo-7-nitro indazole, 1-(2-trifluoromethylphenyl)imidazole, S-methyl-thiocitrulline and 7-nitro indazole, reduced locomotion in mice. These results suggest that activity of NOS and corresponding NO release are of importance for normal locomotion.</description>
    </item>
  </channel>
</rss>